Background: The most important reason for pre-operative administration of medication is to reduce anxiety. Alleviation of fear and anxiety about surgery enables patients to remain comfortable during treatment. Dexmedetomidine (DEX) is a fast-acting drug that is used as a premedication in different circumstances because it has sedative and anti-anxiolytic effects, and stable hemodynamics. It also has the advantage of intranasal administration. The aim of this study was to investigate the effects and hemodynamic stability of DEX by retrospectively analyzing cases in which DEX was administered nasally as a premedication. Methods: Ten patients treated at Dankook University Dental Hospital, recruited between February and April 2015, received intranasal delivery of 2 µg/kg DEX, 30 minutes prior to general anesthesia. Anesthesia records of anxiety, blood pressure, respiration, pulse, estimated arterial oxygen saturation (SpO2), and partial pressure, or maximum concentration, of carbon dioxide (ETCO2) were analyzed. Results: Administration of DEX prior to a general anesthetic effectively relieved anxiety. Respiratory depression, the most severe adverse effect of other sedatives, was not observed. Hemodynamic stability under general anesthesia was maintained during treatment and a reduction in emergence delirium was observed upon completion of treatment. Conclusions: Premedication administration of DEX is safe for pediatric patients undergoing dental treatment under general anesthesia.
INTRODUCTION
The most important purpose of pre-operative medication is to alleviate fear and anxiety about surgery, enabling patients to be maintained comfortably during treatment. In particular, pre-operative medication facilitates general anesthesia in children and in patients for whom communication is challenging, or who have had unpleasant or distressing hospital experiences [1] . Ideal pre-operative medications should be fast-acting, rapidly metabolized, and reliable. Patient respiratory function should be maintained and the drug should be neuroprotective, with minimal cardiovascular effects [2] . The desired effects are sedation, anxiety relief, memory suppression, pain relief, decreased secretion in the airway and the stomach, prevention of aspiration pneumonia, vagus nerve blockade, and prevention of nausea, vomiting, and infection.
Dexmedetomidine (DEX) is a strong and fast-acting alpha-2 adrenergic receptor agonist that is used as a premedication in various circumstances due to its sedative and anti-anxiolytic effects and stable hemodynamics.
Unlike other sedatives, DEX is compatible with intranasal administration and it rarely induces respiratory depression [1] . However, DEX administration has been reported to be associated with adverse effects, such as bradycardia, hypotension, and awareness at rest [2, 3] . It is considered that this mode of delivery may reduce the burning sensation and associated coughing that may occur during intranasal administration [5] .
The aim of this study was to investigate the effects and hemodynamic stability of DEX by retrospectively analyzing cases of intranasal DEX administration as a premedication prior to general anesthesia for dental treatment.
MATERIAL AND METHODS

Subjects
This study was approved by the Institutional Review Table 1 . Written informed consent was obtained from all patients prior to general anesthesia.
Methods
Patient charts were reviewed to obtain information about personal details, type of surgery, premedication, and general anesthesia. All patients received intranasal administration of 2 μg/kg DEX, which was delivered by an atomizer 30 minutes before general anesthesia ( 
RESULTS
Patient gender, age, and body weight are presented in Table 1 . Surgical methods, anesthetic time and treatment time for each patient are presented in Table 2 effectively relieved patient anxiety and there was no incidence of respiratory failure, which is the most severe adverse effect recorded following use of other sedatives.
General anesthesia was induced by constant flow of 3% sevoflurane, which was administered via a warming circuit. Hemodynamically stable blood pressure and heart rate were maintained during treatment (Table 3) 
DISCUSSION
Anxiety in pediatric patients is significant problem.
Anxiety relief is used to manage a patient's distress before, during and after treatment, and may have a great impact on future treatments [5] . Premedication is given to pediatric patients in order to relieve anxiety prior to administration of a general anesthetic. Midazolam is used widely as a premedication in this context; however, DEX was suggested as an alternative because of adverse effects associated with midazolam use, including emergency delirium, reversibility, and negative behavioral changes after surgery procedure [2] .
DEX is a fast-acting alpha-2 adrenergic receptor agonist [1] [2] [3] [4] 7, 8] with few adverse effects due to its short half-life [8] . Respiratory failure, which is a risk factor of most sedatives, occurs more often in obese patients.
Jayaraman et al. [4] reported that there was no incidence of respiratory failure following sedation of obese patients using DEX. Use of sevoflurane in pediatric patients undergoing general anesthesia is associated with a high risk of emergence delirium; although it has been reported that the incidence of emergence delirium is lower when DEX is used [8] . However, this is associated with a temporary increase in blood pressure and reflex bradycardia, with subsequent hypotension. In addition to these adverse effects, nausea, hypoxia, and ventricular tachycardia may also occur [3] . DEX requires intravenous administration, which is not possible for patients who harbor a fear of needles or who are not cooperative. In contrast, intranasal administration enables delivery along the nose-brain pathway, via the olfactory mucosa and the intranasal blood vessels, which provides a fast-acting and useful adjuvant delivery route for sedation [9] [10] [11] . Instillation and spray are the two methods of intranasal drug administration. Instillation has shortcomings that include nasopharyngeal swallowing and discomfort, whereas intranasal spray can enable more even distribution and absorption across a broader mucosal area than intranasal instillation [9] . The intranasal spray (LMA MAD Nasal TM ) used in this study was assembled with a disposable syringe and is sprayed in droplets of 20-100 μm, which is broadly distributed over the mucosa.
The advantages of an intranasal spray are the ease of application (in most cases) and ease of use, as it is readily delivered into the nose without any requirement for specific training.
Premedication with intranasal DEX facilitates the sedation process in uncooperative patients, such as patients with autism [12] . Commonly used oral, intramuscular or intravenous sedation are challenging to administer, as they require the cooperation of the patient, which may be difficult if the patient has a fear of needles or minding in medications. These situations occur more often in pediatric patients. In comparison, intranasal administration permits the treating practitioner to control the patient's movement to a certain degree. Delivery of intranasal drugs permits absorption through the nasal mucosa and into the blood stream [9] . This mode of delivery is fast-acting due to the favorable absorption rate and bioavailibility, even for small doses. The burning sensation and coughing that are associated with intranasal administration were recently reported to be diminished if the medication is delivered by a LMA MAD Nasal TM [9] . In this study, pediatric patients undergoing dental treatment under general anesthetic with sevoflurane and desflurane received an intranasal administration of DEX 
CONCLUSIONS
This study demonstrates that patient anxiety is effectively relieved by administration of DEX prior to general anesthesia, and that this does not induce respiratory depression, which is one of the most severe adverse effects of other sedatives. Analysis of patient outcomes after completion of treatment showed that hemodynamic stability was maintained during general anesthesia and emergence delirium was reduced.
Although additional observation and research are required, this study suggests that premedication administration of DEX is safe for use in dental treatment of pediatric patients receiving general anesthesia.
